BioXcel Therapeutics Income Statement (2022-2025) | BTAI

1Y3Y5Y7Y10YAll
Download Data
Income Statement Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Revenue & cost
Revenue (Quarter) -0.01M-1.59M0.14M0.24M0.21M0.46M0.34M0.38M0.58M1.10M0.21M0.37M0.17M0.12M0.10M0.26M
Gross Profit (Quarter) 0.13M0.23M0.20M0.43M-0.17M-0.34M0.50M1.04M-0.96M-0.47M0.15M0.01M0.09M0.22M
Operating items
Amortization - Deferred Charges (Quarter) 0.32M0.22M0.32M0.33M0.36M0.38M0.31M0.04M0.10M0.11M0.22M0.35M0.39M0.44M0.47M
Research & Development (Quarter) 18.56M17.91M22.06M32.46M27.80M26.97M19.62M9.93M11.40M8.03M5.10M5.90M4.55M10.26M8.74M6.70M
Selling, General & Administrative (Quarter) 12.92M18.38M17.05M20.66M23.59M25.87M24.34M9.60M13.26M9.45M7.68M4.09M5.70M5.61M5.38M3.81M
Restructuring Costs (Quarter) 4.16M0.86M1.55M0.03M0.19M
Other Operating Expenses (Quarter) 0.01M0.01M0.01M0.03M0.51M0.71M0.08M0.06M1.17M0.83M0.01M0.11M0.01M0.03M
Operating Expenses (Quarter) 31.48M36.29M39.13M53.13M51.40M52.87M48.64M20.25M24.75M18.40M15.51M10.86M10.27M15.97M14.33M10.54M
Operating Income (Quarter) -31.48M-36.29M-38.99M-52.89M-51.20M-52.41M-48.30M-19.88M-24.16M-17.30M-15.29M-10.49M-10.10M-15.85M-14.23M-10.28M
EBIT (Quarter) -31.48M-36.29M-38.99M-52.89M-51.20M-52.41M-48.30M-19.88M-24.16M-17.30M-15.29M-10.49M-10.10M-15.85M-14.23M-10.28M
Non-operating items
Interest & Investment Income (Quarter) 0.01M0.20M0.82M1.49M2.02M1.62M1.07M0.95M0.95M0.67M0.62M0.37M0.28M0.23M0.24M0.32M
Other Non Operating Income (Quarter) 0.06M-0.48M-0.25M0.54M-0.01M0.11M0.03M12.03M4.82M3.30M6.56M0.66M-12.55M1.81M
Non Operating Income (Quarter) 0.06M-0.48M-0.25M0.54M-0.01M0.11M0.03M12.03M4.82M3.30M6.56M0.66M-12.55M1.81M
Net income details
EBT (Quarter) -31.47M-37.67M-41.87M-53.47M-52.22M-54.05M-50.48M-20.99M-26.82M-20.32M-18.47M-14.40M-13.46M-19.45M-18.36M-13.89M
Profit After Tax (Quarter) -31.47M-37.67M-41.80M-54.81M-52.80M-53.52M-50.49M-22.26M-26.79M-8.30M-13.65M-10.86M-7.25M-19.19M-30.91M-12.54M
Income from Continuing Operations (Quarter) -31.47M-37.67M-41.87M-53.47M-52.22M-54.05M-50.48M-20.99M-26.82M-20.32M-18.47M-14.40M-13.46M-19.45M-18.36M-13.89M
Consolidated Net Income (Quarter) -31.47M-37.67M-41.87M-53.47M-52.22M-54.05M-50.48M-20.99M-26.82M-20.32M-18.47M-14.40M-13.46M-19.45M-18.36M-13.89M
Income towards Parent Company (Quarter) -31.47M-37.67M-41.87M-53.47M-52.22M-54.05M-50.48M-20.99M-26.82M-20.32M-18.47M-14.40M-13.46M-19.45M-18.36M-13.89M
Net Income towards Common Stockholders (Quarter) -31.47M-37.67M-41.87M-53.47M-52.22M-54.05M-50.48M-20.99M-26.82M-20.32M-18.47M-14.40M-13.46M-19.45M-18.36M-13.89M
Additional items
EPS (Basic) (Quarter) -1.12-1.35-1.49-1.96-1.84-1.83-1.72-92.93-13.89-3.30-5.15-2.91-1.50-2.45-2.180.65
EPS (Weighted Average and Diluted) (Quarter) -1.12-1.35-1.49-1.96-1.84-1.83-1.72-92.93-13.89-3.30-5.15-2.91-1.50-2.45-2.180.65
Shares Outstanding (Weighted Average) (Quarter) 27.98M27.98M28.02M28.02M28.62M28.90M29.27M1.82M1.93M2.52M2.65M2.54M4.83M6.35M8.99M12.21M
Shares Outstanding (Diluted Average) (Quarter) 0.03M27.98M28.02M28.02M28.62M28.90M29.27M1.82M1.93M2.22M2.37M2.54M4.83M7.84M8.99M12.21M
EBITDA (Quarter) -31.48M-36.29M-38.99M-52.89M-51.20M-52.41M-48.30M-19.88M-24.16M-17.30M-15.29M-10.49M-10.10M-15.85M-14.23M-10.28M
Interest Expenses (Quarter) 0.01M1.59M3.70M2.06M3.03M3.26M3.25M2.06M3.61M3.70M3.79M4.28M3.64M3.83M4.37M3.93M
Shares Outstanding (Quarter) 27.98M28.02M28.02M1.76M29.10M29.27M29.27M1.87M2.10M2.52M2.65M3.10M5.47M6.62M20.00M22.33M